Cronos Group Competitors

Canopy Growth (NASDAQ:CGC) and Cronos Group (NASDAQ:CRON) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, institutional ownership and profitability.

Volatility and Risk

Canopy Growth has a beta of 2.44, meaning that its stock price is 144% more volatile than the S&P 500. Comparatively, Cronos Group has a beta of 2.07, meaning that its stock price is 107% more volatile than the S&P 500.

Valuation and Earnings

This table compares Canopy Growth and Cronos Group's revenue, earnings per share (EPS) and valuation.

Cronos Group has lower revenue, but higher earnings than Canopy Growth. Cronos Group is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Canopy Growth and Cronos Group's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings for Canopy Growth and Cronos Group, as reported by MarketBeat.com.

Canopy Growth currently has a consensus price target of $38.5667, indicating a potential upside of 24.37%. Cronos Group has a consensus price target of $8.8333, indicating a potential downside of 8.37%. Given Canopy Growth's stronger consensus rating and higher possible upside, analysts clearly believe Canopy Growth is more favorable than Cronos Group.

Insider and Institutional Ownership

10.2% of Canopy Growth shares are held by institutional investors. Comparatively, 11.8% of Cronos Group shares are held by institutional investors. 0.3% of Canopy Growth shares are held by insiders. Comparatively, 7.9% of Cronos Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Cronos Group beats Canopy Growth on 8 of the 15 factors compared between the two stocks.

Cronos Group (NASDAQ:CRON) and Aphria (NASDAQ:APHA) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

Analyst Recommendations

This is a breakdown of current recommendations for Cronos Group and Aphria, as provided by MarketBeat.

Cronos Group currently has a consensus target price of $8.8333, indicating a potential downside of 8.37%. Aphria has a consensus target price of $17.7857, indicating a potential upside of 6.44%. Given Aphria's stronger consensus rating and higher possible upside, analysts plainly believe Aphria is more favorable than Cronos Group.

Volatility and Risk

Cronos Group has a beta of 2.07, indicating that its share price is 107% more volatile than the S&P 500. Comparatively, Aphria has a beta of 2.67, indicating that its share price is 167% more volatile than the S&P 500.

Profitability

This table compares Cronos Group and Aphria's net margins, return on equity and return on assets.

Insider & Institutional Ownership

11.8% of Cronos Group shares are owned by institutional investors. Comparatively, 10.3% of Aphria shares are owned by institutional investors. 7.9% of Cronos Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Cronos Group and Aphria's top-line revenue, earnings per share (EPS) and valuation.

Cronos Group has higher earnings, but lower revenue than Aphria. Aphria is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Summary

Cronos Group beats Aphria on 9 of the 14 factors compared between the two stocks.

Cronos Group (NASDAQ:CRON) and Tilray (NASDAQ:TLRY) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, risk, institutional ownership, profitability, valuation and earnings.

Insider and Institutional Ownership

11.8% of Cronos Group shares are held by institutional investors. Comparatively, 12.6% of Tilray shares are held by institutional investors. 7.9% of Cronos Group shares are held by company insiders. Comparatively, 16.8% of Tilray shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility and Risk

Cronos Group has a beta of 2.07, suggesting that its stock price is 107% more volatile than the S&P 500. Comparatively, Tilray has a beta of 3.12, suggesting that its stock price is 212% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Cronos Group and Tilray, as reported by MarketBeat.

Cronos Group currently has a consensus price target of $8.8333, indicating a potential downside of 8.37%. Tilray has a consensus price target of $18.3078, indicating a potential downside of 19.17%. Given Cronos Group's stronger consensus rating and higher possible upside, research analysts clearly believe Cronos Group is more favorable than Tilray.

Profitability

This table compares Cronos Group and Tilray's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Cronos Group and Tilray's gross revenue, earnings per share (EPS) and valuation.

Cronos Group has higher earnings, but lower revenue than Tilray. Tilray is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Summary

Cronos Group beats Tilray on 10 of the 14 factors compared between the two stocks.

USANA Health Sciences (NYSE:USNA) and Cronos Group (NASDAQ:CRON) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings and valuation.

Profitability

This table compares USANA Health Sciences and Cronos Group's net margins, return on equity and return on assets.

Insider & Institutional Ownership

54.1% of USANA Health Sciences shares are held by institutional investors. Comparatively, 11.8% of Cronos Group shares are held by institutional investors. 45.4% of USANA Health Sciences shares are held by insiders. Comparatively, 7.9% of Cronos Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Risk and Volatility

USANA Health Sciences has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500. Comparatively, Cronos Group has a beta of 2.07, meaning that its stock price is 107% more volatile than the S&P 500.

Valuation and Earnings

This table compares USANA Health Sciences and Cronos Group's revenue, earnings per share and valuation.

Cronos Group has lower revenue, but higher earnings than USANA Health Sciences. Cronos Group is trading at a lower price-to-earnings ratio than USANA Health Sciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for USANA Health Sciences and Cronos Group, as provided by MarketBeat.

USANA Health Sciences presently has a consensus target price of $126.00, indicating a potential upside of 25.82%. Cronos Group has a consensus target price of $8.8333, indicating a potential downside of 8.37%. Given USANA Health Sciences' stronger consensus rating and higher probable upside, research analysts plainly believe USANA Health Sciences is more favorable than Cronos Group.

Summary

USANA Health Sciences beats Cronos Group on 8 of the 13 factors compared between the two stocks.

Aurora Cannabis (NYSE:ACB) and Cronos Group (NASDAQ:CRON) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, risk, profitability and institutional ownership.

Volatility & Risk

Aurora Cannabis has a beta of 3.44, indicating that its stock price is 244% more volatile than the S&P 500. Comparatively, Cronos Group has a beta of 2.07, indicating that its stock price is 107% more volatile than the S&P 500.

Profitability

This table compares Aurora Cannabis and Cronos Group's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Aurora Cannabis and Cronos Group, as provided by MarketBeat.

Aurora Cannabis presently has a consensus price target of $11.2445, indicating a potential upside of 14.51%. Cronos Group has a consensus price target of $8.8333, indicating a potential downside of 8.37%. Given Aurora Cannabis' higher possible upside, equities analysts plainly believe Aurora Cannabis is more favorable than Cronos Group.

Valuation and Earnings

This table compares Aurora Cannabis and Cronos Group's gross revenue, earnings per share and valuation.

Cronos Group has lower revenue, but higher earnings than Aurora Cannabis. Aurora Cannabis is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

11.9% of Aurora Cannabis shares are owned by institutional investors. Comparatively, 11.8% of Cronos Group shares are owned by institutional investors. 7.9% of Cronos Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Cronos Group beats Aurora Cannabis on 10 of the 14 factors compared between the two stocks.

Cronos Group (NASDAQ:CRON) and Sundial Growers (NASDAQ:SNDL) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.

Volatility and Risk

Cronos Group has a beta of 2.07, meaning that its stock price is 107% more volatile than the S&P 500. Comparatively, Sundial Growers has a beta of 7.01, meaning that its stock price is 601% more volatile than the S&P 500.

Profitability

This table compares Cronos Group and Sundial Growers' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings for Cronos Group and Sundial Growers, as reported by MarketBeat.

Cronos Group presently has a consensus target price of $8.8333, indicating a potential downside of 8.37%. Sundial Growers has a consensus target price of $1.00, indicating a potential downside of 13.79%. Given Cronos Group's stronger consensus rating and higher probable upside, research analysts clearly believe Cronos Group is more favorable than Sundial Growers.

Valuation & Earnings

This table compares Cronos Group and Sundial Growers' top-line revenue, earnings per share (EPS) and valuation.

Cronos Group has higher earnings, but lower revenue than Sundial Growers. Sundial Growers is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

11.8% of Cronos Group shares are held by institutional investors. Comparatively, 3.3% of Sundial Growers shares are held by institutional investors. 7.9% of Cronos Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Cronos Group beats Sundial Growers on 12 of the 14 factors compared between the two stocks.